MA50383A - Agents thérapeutiques pour maladies neurodégénératives - Google Patents

Agents thérapeutiques pour maladies neurodégénératives

Info

Publication number
MA50383A
MA50383A MA050383A MA50383A MA50383A MA 50383 A MA50383 A MA 50383A MA 050383 A MA050383 A MA 050383A MA 50383 A MA50383 A MA 50383A MA 50383 A MA50383 A MA 50383A
Authority
MA
Morocco
Prior art keywords
therapeutic agents
neurodegenerative diseases
neurodegenerative
diseases
therapeutic
Prior art date
Application number
MA050383A
Other languages
English (en)
Other versions
MA50383B1 (fr
Inventor
Mallory Factor
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA50383A publication Critical patent/MA50383A/fr
Publication of MA50383B1 publication Critical patent/MA50383B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
MA50383A 2017-10-18 2018-02-15 Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos MA50383B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574137P 2017-10-18 2017-10-18
EP18708286.2A EP3697399B1 (fr) 2017-10-18 2018-02-15 Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos
PCT/US2018/018420 WO2019078915A1 (fr) 2017-10-18 2018-02-15 Agents thérapeutiques pour maladies neurodégénératives

Publications (2)

Publication Number Publication Date
MA50383A true MA50383A (fr) 2020-08-26
MA50383B1 MA50383B1 (fr) 2026-01-30

Family

ID=66174216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50383A MA50383B1 (fr) 2017-10-18 2018-02-15 Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos

Country Status (24)

Country Link
US (1) US11793782B2 (fr)
EP (2) EP4467138A3 (fr)
JP (1) JP2021500342A (fr)
KR (1) KR102549684B1 (fr)
CN (1) CN111542314B (fr)
AU (1) AU2018351709B2 (fr)
CA (1) CA3079194A1 (fr)
DK (1) DK3697399T3 (fr)
ES (1) ES3057584T3 (fr)
FI (1) FI3697399T3 (fr)
HR (1) HRP20251695T1 (fr)
IL (1) IL273929B2 (fr)
LT (1) LT3697399T (fr)
MA (1) MA50383B1 (fr)
MD (1) MD3697399T2 (fr)
MX (1) MX2020003427A (fr)
PL (1) PL3697399T3 (fr)
PT (1) PT3697399T (fr)
RS (1) RS67601B1 (fr)
RU (1) RU2763425C2 (fr)
SG (1) SG11202003390UA (fr)
SI (1) SI3697399T1 (fr)
SM (1) SMT202500483T1 (fr)
WO (1) WO2019078915A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
MA51836B1 (fr) * 2018-02-15 2025-01-31 Intrabio Ltd Agents thérapeutiques permettant de traiter le syndrome des jambes sans repos
WO2025163129A1 (fr) * 2024-02-01 2025-08-07 Intrabio Ltd. Acétylleucine pour le traitement de la maladie de parkinson
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004080393A2 (fr) * 2003-03-06 2004-09-23 Celgene Corporation Methodes d'utilisation et compositions comprenant des medicaments selectifs inhibitoires de cytokine pour le traitement et pour la gestion de troubles du systeme nerveux central
RU2458049C2 (ru) * 2003-09-17 2012-08-10 Ксенопорт, Инк. Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк
EP2977452A3 (fr) * 2007-05-11 2016-05-25 Thomas Jefferson University Procédés de traitement et de prévention de maladies et de troubles neurodégénératifs
EP2289886A1 (fr) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoides agonistes du facteur de croissance nerveuse et leur utilisation en tant que médicaments
CA2785056A1 (fr) * 2009-12-22 2011-07-21 Pondera Biotechnologies, LLC Methodes et compositions pour le traitement de la detresse dysfonctionnelle et l'augmentation de la securite et de l'efficacite de medicaments specifiques
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
LT2588130T (lt) 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
WO2015129527A1 (fr) * 2014-02-27 2015-09-03 株式会社メドレックス Timbre transdermique contenant du pramipexole pour le traitement d'une maladie neurodégénérative
DE102016000393A1 (de) 2015-10-01 2017-04-06 Linde Aktiengesellschaft Verfahren zum Verflüssigen einer Kohlenwasserstoff-reichen Fraktion
WO2018029658A1 (fr) * 2016-08-11 2018-02-15 Intrabio Limited Agents thérapeutiques pour maladies neurodégénératives

Also Published As

Publication number Publication date
LT3697399T (lt) 2026-01-12
PT3697399T (pt) 2025-12-24
HRP20251695T1 (hr) 2026-02-27
BR112020007657A2 (pt) 2020-09-29
IL273929B1 (en) 2024-07-01
EP4467138A3 (fr) 2025-02-26
RU2020115710A3 (fr) 2021-11-18
JP2021500342A (ja) 2021-01-07
IL273929A (en) 2020-05-31
WO2019078915A1 (fr) 2019-04-25
US11793782B2 (en) 2023-10-24
PL3697399T3 (pl) 2026-03-23
FI3697399T3 (fi) 2026-01-08
CN111542314B (zh) 2023-11-24
SI3697399T1 (sl) 2026-02-27
SMT202500483T1 (it) 2026-01-12
CA3079194A1 (fr) 2019-04-25
DK3697399T3 (da) 2025-12-22
EP3697399B1 (fr) 2025-11-26
IL273929B2 (en) 2024-11-01
MA50383B1 (fr) 2026-01-30
KR102549684B1 (ko) 2023-06-29
CN111542314A (zh) 2020-08-14
AU2018351709A1 (en) 2020-05-07
MX2020003427A (es) 2020-09-14
MD3697399T2 (ro) 2026-02-28
AU2018351709B2 (en) 2024-01-04
EP3697399A1 (fr) 2020-08-26
SG11202003390UA (en) 2020-05-28
US20210196659A1 (en) 2021-07-01
RU2763425C2 (ru) 2021-12-29
KR20200074170A (ko) 2020-06-24
RS67601B1 (sr) 2026-01-30
RU2020115710A (ru) 2021-11-18
ES3057584T3 (en) 2026-03-03
EP4467138A2 (fr) 2024-11-27

Similar Documents

Publication Publication Date Title
MA47521A (fr) Agents thérapeutiques pour maladies neurodégénératives
GB201820166D0 (en) Therapeutic agents
GB201820165D0 (en) Therapeutic agents
GB201709456D0 (en) Therapeutic agents
IL270916A (en) Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
EP3735463A4 (fr) Agent thérapeutique induisant une cytotoxicité
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
GB201805816D0 (en) Therapeutic agents
SG11202103250UA (en) Therapeutic agent for neurodegenerative disease
IL273929A (en) Therapeutic agents for neurodegenerative diseases
EP3371210A4 (fr) Polythérapie pour maladies malignes
EP3634394A4 (fr) Compositions pour le traitement de maladies neurodégénératives
EP3828546A4 (fr) Composition pour diagnostiquer des maladies
GB201700553D0 (en) Therapeutic agents
EP2949329A4 (fr) Agent thérapeutique pour maladies démyélinisantes
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives
EP3846816A4 (fr) Agents neuroprotecteurs pour le traitement de maladies neurodégénératives
EP3903882A4 (fr) Agent thérapeutique pour bradyarhytmie héréditaire
EP3508214A4 (fr) Agent thérapeutique pour maladies ischémiques.
EP3731854A4 (fr) Agents thérapeutiques de protéines de fusion ptd-smad7
EP3399999A4 (fr) Thérapeutique pour maladies immuno-inflammatoires oculaires
EP3539561A4 (fr) Agent thérapeutique pour infarctus cérébral
GB201820172D0 (en) Therapeutic agents